🐾 Vasotop R tablets 0.625 mg, 3 vials of 28 pcs.

Vasotop R is a hypotensive drug.

Ramipril, a part of the drug, is an inhibitor of angiotensin-converting enzyme (ACE), which by inhibiting the synthesis of angiotensin II, reduces its vasoconstrictor effect and stimulating effect on aldosterone secretion, and inhibits bradykinin breakdown.

Ramipril has no significant effect on renal blood flow (in some cases it increases it) and on glomerular filtration rate. The drug does not cause compensatory tachycardia.

Maximum hypotensive effect occurs 1 to 3 hours after drug intake and lasts during the day. With daily use of Vasotop R decrease of blood pressure occurs gradually over 3-4 weeks and remains within physiological norms during the whole period of treatment. Abrupt withdrawal of the drug does not lead to a rapid increase in blood pressure.

Vasotop R has a cardioprotective effect due to ACE inhibition in myocardium and bradykinin accumulation and promotes the reverse development of myocardial hypertrophy in animals with arterial hypertension.

After oral administration, ramipril is rapidly absorbed in an amount equal to at least 50-60% of the administered dose. Primary metabolism of ramipril occurs in the liver. This produces ramipril derivative – ramiprilate.

Ramiprilat is about 6 times more active inhibitor of ACE than ramipril. Binding to plasma proteins is 73% for ramipril and 56% for ramiprilat. After a daily single dose of Vasotop P, the steady-state plasma concentration of ramiprilat is reached by day 4. About 60% of the drug is excreted with the urine and about 40% – with the feces (mainly as metabolites).

In patients with impaired renal function excretion of ramipril and its metabolites slows down in proportion to the decrease in creatinine clearance. According to the degree of effect on the body of warm-blooded animals, Vasotop R belongs to the low-hazardous substances.

Indications

Prescribed for dogs in diseases of the respiratory, urogenital and digestive systems, as well as soft tissues and otitis, infected wounds whose pathogens are sensitive to enrofloxacin.

Active ingredient

Ramipril

Composition

Vasotop P as an active ingredient contains ramipril 0.625 mg and excipients: hypromellose 0.110 mg, pregelatinized starch 42.765 mg, microcrystalline cellulose 44.5 mg, powdered beef flavoring 10 mg, sodium stearyl fumarate 0.50 mg, colloidal silicon anhydride 0.50 mg and iron oxide 1.0 mg.

Directions for use

Vasotop R is administered orally once a day, on an empty stomach. Initial therapeutic dose for dogs per day is 0.125 mg of the active substance ramipril per 1 kg of animal weight. Animals weighing more than 50 kg may be given a daily dose of the drug in two doses. After normalization of blood pressure the drug treatment shall be continued in half dose of the initial one. In animals with risk of hypovolemia, treatment with Vasotop R shall be started with half dose given during one week. If there is no reduction of blood pressure against the background of Vasotop P administration, simultaneous use of diuretics (except potassium-saving) in doses according to the instructions for use is allowed to enhance the therapeutic effect. In case of congestion in the lungs, two weeks after the start of the drug, the daily dose may be increased to 0.25 mg of ramipril per 1 kg of animal weight. The duration of the course of therapy is determined by the veterinarian.

Vasotop R in cats is prescribed if the cause that caused the increase in blood pressure (e.g., hyperthyroidism) cannot be eliminated. Treatment with Vasotop P should be carried out under the regular supervision of a veterinarian (once every 7-14 days).

In cats with severe eye lesions or rapidly progressing neurological symptoms (due to pressure elevation), clinical evaluation every 1-2 days is recommended.

The duration of treatment with Vasotop R is determined by the veterinarian.

Special Instructions

Animals with an increased risk of developing excessive hypotension after the first dose, as well as after increasing the dose of the drug should be under close supervision of the veterinarian, especially during the first 2 weeks of treatment.

In case of the development of hypotension, ataxia, tachycardia, arrhythmia and angina, treatment with Vasotop R should be discontinued.

Diuretics and a low-sodium diet enhance the effects of the drug, so to avoid the development of severe hypotension accompanied by apathy, ataxia, syncope, or acute renal failure, do not exceed the doses of diuretics and prescribe a low-sodium diet.

Simultaneous use with potassium-containing drugs is not recommended because it may lead to the development of hyperkalemia in the body.

Contraindications

Increased individual sensitivity to the components of the drug. Mitral valve stenosis, aortic stenosis, hypertensive cardiomyopathy, severe liver and kidney dysfunction. It is not recommended to use the drug in lactating and puppy animals.

Side effects

In some cases, against the background of the drug use, the animal may experience adverse effects of the respiratory system (sinusitis, rhinitis, bronchospasm), the gastrointestinal tract (nausea, dyspepsia, vomiting, diarrhea, constipation, dysphagia, loss of appetite), the nervous system (seizures, neuralgia, neuropathy, paresthesia, tremor).